ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2029

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

RSI MRI

In ART-Pro-1, patients receive standard of care mpMRI, with addition of the RSI sequence, and subsets of the patients' images are read separately by two expert radiologists at the center, one of whom is the standard of care radiologist (Reader 1). Three research reports are generated using: bpMRI only (Reader 1), mpMRI (Reader 1), and bpMRI + RSIrs (Reader 2). The clinical report is submitted by Reader 1. Patients' future prostate cancer management will be recorded and used to evaluate the performance of the MRI techniques being tested.

Trial Locations (5)

10065

NOT_YET_RECRUITING

Weill Cornell Medical College, New York

92037

RECRUITING

University of California San Diego, San Diego

94143

NOT_YET_RECRUITING

University of California, San Francisco, San Francisco

02114

NOT_YET_RECRUITING

Massachusetts General Hospital, Boston

CB2 0QQ

NOT_YET_RECRUITING

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

collaborator

University of California, San Francisco

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

lead

University of California, San Diego

OTHER

NCT06579417 - ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer | Biotech Hunter | Biotech Hunter